Sarepta Therapeutics Inc

Skip to main content

Company

Sarepta Therapeutics Inc

15 results

Healthcare & PharmaceuticalscategorySarepta says FDA may limit gene therapy nod to smaller population, shares fallMay 24, 2023
BusinesscategoryCatalent cuts forecast, delays results again as challenges mountMay 19, 2023
MarketscategoryAnalysis: Amgen's antitrust woes spur wider pharmaceutical deal fearsMay 17, 2023
MarketscategoryFTC sues to block Amgen's $27.8 billion deal for Horizon TherapeuticsMay 16, 2023
BusinesscategorySarepta surges after FDA panel backs Duchenne gene therapyMay 15, 2023
Healthcare & PharmaceuticalscategoryUS FDA advisers narrowly back Sarepta's Duchenne gene therapy for accelerated approvalMay 12, 2023
Future of HealthcategoryFDA reviewers raise doubts over data on Sarepta's gene therapyMay 10, 2023
BusinesscategorySarepta drops as report says FDA almost rejected under-review gene therapyApril 13, 2023
WorldcategoryUS FDA to take steps to help gene therapies get accelerated approvalMarch 21, 2023
BusinesscategorySarepta slides as FDA about-turn on panel clouds gene therapy approval pathMarch 17, 2023
BusinesscategoryReata shares triple after surprise FDA nod for rare disease drugMarch 1, 2023
MarketscategoryWall Street ends down sharply, hit by Apple and China worriesNovember 29, 2022
BusinesscategoryJPMorgan moves healthcare conference online amid Omicron concernsDecember 15, 2021
WorldcategoryThird member of U.S. FDA advisory panel resigns over Alzheimer’s drug approvalJune 11, 2021
BusinesscategoryBig Biogen boost on Alzheimer's news could win back biotech investorsJune 7, 2021

1 to 15 of 15